tert-Butyl 5-methyl-3-(2-oxo-4-(pyridin-2-ylmethoxy)pyridin-1(2H)-yl)-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole-11-carboxylate | 1260400-39-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: tert-Butyl 5-methyl-3-(2-oxo-4-(pyridin-2-ylmethoxy)pyridin-1(2H)-yl)-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole-11-carboxylate
• 英文别名: Tert-butyl 9-methyl-6-[2-oxo-4-(pyridin-2-ylmethoxy)pyridin-1-yl]-9,15-diazatetracyclo[10.2.1.02,10.03,8]pentadeca-2(10),3(8),4,6-tetraene-15-carboxylate；tert-butyl 9-methyl-6-[2-oxo-4-(pyridin-2-ylmethoxy)pyridin-1-yl]-9,15-diazatetracyclo[10.2.1.02,10.03,8]pentadeca-2(10),3(8),4,6-tetraene-15-carboxylate
• CAS: 1260400-39-2
• 化学式: C₃₀H₃₂N₄O₄
• 分子量: 512.608
• InChiKey: WEGIKOALZVYMRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  38
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  76.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-(pyridin-2-ylmethoxy)pyridin-2(1H)-one 、 tert-butyl 3-bromo-5-methyl-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole-11-carboxylate 以47%的产率得到tert-Butyl 5-methyl-3-(2-oxo-4-(pyridin-2-ylmethoxy)pyridin-1(2H)-yl)-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole-11-carboxylate
  参考文献：
  名称：

  AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF

  摘要：

  揭示了新型MCH-1受体拮抗剂。这些化合物用于治疗各种疾病，包括肥胖、焦虑、抑郁、非酒精性脂肪肝病和精神障碍。本发明还描述了制备这些化合物的方法。

  公开号：

  US20110003737A1

文献信息

• [EN] AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF<br/>[FR] ANTAGONISTES DE MCH-1 D’AZABICYCLOALCANE-INDOLE ET D’AZABICYCLOALCANE-PYRROLO-PYRIDINE, PROCÉDÉS DE PRÉPARATION, ET UTILISATION DE CEUX-CI
  申请人：ALBANY MOLECULAR RES INC

  公开号：WO2011003007A1

  公开（公告）日：2011-01-06

  Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.